Stem Cell Clinic

University of Wisconsin Researchers Use Stem Cells to Treat Parkinson’s – Gilmore Health News

By Stem Cell Medicine

Parkinsons is a progressive neurodegenerative disorder that characteristically affects the dopamine-producing neurons in the substantia nigra or the midbrain. It usually begins with stiffness, shaking, tremors, voice changes, and postural instability, all of which worsen with time, resulting in difficulty walking and talking.

Man With Parkinsons

Parkinsons is a widely common neurodegenerative disease affecting approximately 10 million people worldwide, as of 2019. And the rate of incidence increases with age, for example, it affects 1 percent of individuals over the age of 60 years in comparison to 5 percent of individuals over the age of 85 years.

Read Also: Parkinsons Disease: A Promising Treatment Thanks to Stem Cells

Parkinsons is a nervous system disorder that predominantly affects the motor function of the patient, therefore reducing the quality of life significantly. Unfortunately, Parkinson does not have a cure but there are many supportive therapeutic options available for the patients in the form of physical therapy, and medication along with a treatment option including deep brain stimulation (DBS).

DBS has shown great results but it is an invasive procedure that only produces temporary results. Hence, more research and studies need to be performed in the field of nervous system disorders to discover better therapeutic approaches.

Parkinsons and other nervous system disorders like stroke, Huntingtons, and so on are difficult to cure or treat due to the extensive damage to the neurons seen in these diseases. This is a problem because neurons are infamous for their inability to regenerate. Although stem cells that can be adapted into neurons may be recommended as a therapeutic option, they come with a problem of their own.

The new neurons do not connect with the native neurons as they do not recognize or identify them. This results in no improvement in neuronal circuitry and in the patients condition.

A recent study published in Cell Stem Cell Journal by Su-Chun Zhang, Department of Neuroscience, School of Medicine and Public Health, University of Wisconsin-Madison, and her team claim to have derived neurons from human stem cells that can be used to repair circuitry and improve neural functions.

Read Also: Antibiotics May Increase Your Risk of Having Parkinsons Disease

Zhang and her team derived dopamine-producing neurons from human embryonic stem cells and then transplanted these into the substantia nigra of the brain in animal models with Parkinsons disease.

These transplanted cells also contained on and off switches that could be stimulated externally using certain drugs or foods.

Zhang and her team found that these transplanted cells formed connections with native neurons and grew long-distance to form connections with the motor control regions in the brain to improve the motor functions usually affected by Parkinsons. The results were visible after a few months of transplantation, the time needed for the transplanted neurons to integrate into the brain.

To confirm that the improvement seen in the mice was due to the transplanted cells, the on and off switches were stimulated by the research team.

Read Also: Implants from Own Stem Cells May Offer Solution to Back Pain, Researchers Say

When the cells were turned off, the symptoms of Parkinsons reappeared indicating the proper functioning of these cells in the treatment of the neurodegenerative disorder. Furthermore, the scientists on closer look found that these cells were identified by native neurons and had been integrated into the midbrain. Moreover, the researchers believe that these switches can be used to fine-tune the treatment option for the patients.

The research team is currently applying these results to the primates model and aims to use the results from Parkison disease models for other nervous system disorders as well.

Human Stem Cell-Derived Neurons Repair Circuits and Restore Neural Function

Medical University of Vienna: Vitamin B1 May Help Prevent Alcohol-Related Dementia

Old Human Cells Successfully Rejuvenated Via Stem Cell Technology

Is NAD+ The Anti Aging Substance Mankind Has Been Searching For?

Anti-Aging: A New Way to Repair Age Related DNA Damage Discovered

Anti-Aging: HGH Can Reduce Biological Age by One Year and a Half Study Shows

Genf20 Plus Review: Why Are People Rushing to Buy This HGH Supplement?

University of Utah: Could Slowing the Rate of DNA Mutations Be the Key to the Elusive Fountain of Youth

Follow this link:
University of Wisconsin Researchers Use Stem Cells to Treat Parkinson's - Gilmore Health News

Cartilage Repair/ Cartilage Regeneration Market worth $1,603 million by 2025 – Exclusive Report by MarketsandMarkets – PRNewswire

By Stem Cell Medicine

CHICAGO, Oct. 9, 2020 /PRNewswire/ -- According to the new market research report "Cartilage Repair/ Cartilage Regeneration Market by Treatment modalities (Cell based Type (Chondrocyte Transplantation, Growth Factor), Non-Cell (Tissue Scaffolds)), Application (Hyaline), End User (ASCs, Clinic), Site (Knee) - Global Forecast to 2025", published by MarketsandMarkets, the Cartilage Repair/ Cartilage Regeneration Marketis projected to reach USD 1,603 million by 2025 from USD 787 million in 2020, at a CAGR of 15.3% during the forecast period.

Browse in-depth TOC on "Cartilage Repair/ Cartilage Regeneration Market"

144 Tables 41 Figures 157 Pages

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37493272

The growth of this market is primarily driven by the increasing incidence of osteoarthritis and increasing funding and investments for research in this field.

The cell-based segment accounted for the largest share of the treatment modality segment in the market in 2019.

Based on the treatment modality, the cartilage repair market is segmented into cell-based and non-cell-based approaches. The non-cell-based segment is divided into tissue scaffolds and cell-free composites. In 2019, the cell-based segment accounted for the largest share of the cartilage regeneration market. The large share of this segment can be attributed to technological advancements in stem cell-based therapies for cartilage repair and chondrocyte implantation products

The hospitals segment accounted for the largest share of the end user segment in the cartilage repair market in 2019.

Based on end users, the cartilage regeneration market is segmented into hospitals and ambulatory surgery centers (ASCs) and clinics. The hospitals segment accounted for the largest share of the market in 2019. This can be attributed to the large number of minimally invasive surgeries performed in hospitals and the growing number of hospitals in emerging economies.

Get 10% Customization on this Research Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=37493272

The Asia Pacific region is the fastest growing region of the cartilage repair and regeneration market in 2019.

The Asia Pacific region is estimated to grow at the highest CAGR in the cartilage repair market during the forecast period, this is mainly due to the rising geriatric population and the subsequent increase in the incidence of various disorders and injuries. Recent developments in tissue engineering and stem cell therapy will further fuel market growth.

Prominent players in the cartilage regeneration market are Smith & Nephew plc (UK), DePuy Synthes (US), Zimmer Biomet (US), CONMED Corporation (US), Stryker Corporation (US), and Vericel Corporation (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports:

https://www.marketsandmarkets.com/RequestBundleReport.asp?id=37493272

Browse Related Reports:

Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025

https://www.marketsandmarkets.com/Market-Reports/regenerative-medicine-market-65442579.html

Arthroscopy Instruments Market by Type (Implants, Arthroscope, Visualization System, Surgical Shaver, RF Ablation, Fluid Management), Application (Knee, Hip, Shoulder), End User (Hospitals, Ambulatory Surgery Centers & Clinics) - Global Forecast to 2022

https://www.marketsandmarkets.com/Market-Reports/arthroscopy-instrument-market-238516643.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Aashish Mehra MarketsandMarkets INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [emailprotected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cartilage-repair-regeneration-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/cartilage-repair-regeneration.asp

SOURCE MarketsandMarkets

Read more:
Cartilage Repair/ Cartilage Regeneration Market worth $1,603 million by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire

Mission: a cure to cancer – Innovation Origins

By Stem Cell Medicine

Half of the total Dutch production value in Life Sciences & Health (around ten billion euros) is accounted for by the province of North Brabant, a recent report commissioned by the Brabant Development Fund BOM showed. Biotech, in particular, is growing rapidly: the number of new establishments has grown by 43% since 2014 and the number of jobs in this industry has doubled. Today, we take a closer look at one of the examples of this trend: Glycostem.

Roughly, there are three ways to fight cancer. Best known at the moment is chemotherapy, a chemical treatment that unfortunately kills good cells and bad cells at the same time. It has so many unwanted side effects that some experts argue that nowadays it wouldnt even receive approval as a treatment. Next, there are biological products. They are a step forwards, but not a cure. Biological immunotherapy can delay the end of therapy for cancer patients, which is already great. The third way could be the most interesting and promising one: cellular therapy. It contains the ultimate objective, curing cancer all the way. This is where Glycostem Therapeutics, based on Pivot Park Oss, comes in.

Glycostem is focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, Glycostem claims. Due to their tightly regulated natural killing of cancer cells, they play an important role in the control and even cure of both solid and hematological malignancies, a statement on its website says. We had a conversation with CEO Troels Jordansen (56), a businessman with a history in a series of cellular therapy companies all over the world.

As a chairman, Troels Jordansen was already involved in Glycostem for a couple of years, when he was asked to take on the role as CEO four years ago. Although I knew the company quite well, this came a bit as a surprise to me. But I didnt need to think about the offer very long. There were two reasons why I really wanted to help move this company forward, and both were connected to the medical prospects: first, they had proven that cellular medicine could be moved to a level of cellular immunotherapy, and second, their way of using the human body as a source for raw material was something that really inspired me. And it still does.

Basically, Glycostem takes good cells to combat bad cells in the body. For now, the focus is on two specific cancers: Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM). In pre-clinical trials, the company says it has shown remarkable results. The first clinical trial will start in October. Glycostem received approval to do the tests in four European countries. This is a huge step for us: we can now start treating patients. This is whats driving all of us: see patients live on, who otherwise may have died.

You can hardly imagine a world without cancer, but yes, we want to prove that treatment can become a reality. This is our mission.

From there, Jordansen wants to move to other cancers, including solid tumors. Cancer statistics are cruel. If we start making progress in AML and MM, we can start making progress in other cancers later. And in fifteen to twenty years time there will actually be hope for people who would otherwise have died. Marketing wise, this is also an important step for the company. The solid tumors represent a market that is ten times bigger than that of blood cancers. To give you an idea: US insurance companies now pay up to $450,000 per treatment.

In pre-clinical cell line tests, Jordansen says Glycostem has already shown that NK cells will have an effect on solid tumors as well. In early 2021, we will initiate clinical trials at UMC Amsterdam. We will be generating genetically manipulated NK-cells which will include a target. So if you have breast cancer, the NK-cell will go to the tumor, stay there, and step by step eat away this cancer. Can you imagine?

Jordansen is careful not to use the claim that this will ultimately cure cancer. Still, we have an opportunity to make a dent in the universe, to rephrase Steve Jobs. You can hardly imagine a world without cancer, but yes, we want to prove that treatment can become a reality. This is our mission.

The NK-cell will go to the tumor, stay there, and step by step eat away this cancer. Can you imagine?

In the past years, Glycostem was able to raise 35 million euros in equity, grants, and other deals. The company now employs 45 people, it owns a State-of-the-Art cleanroom and other fit-for-purpose facilities at the Pivot Park campus. Still, fulfilling the ultimate dream is not yet a done deal. We have to be realistic, our success still depends on factors which we cannot control completely. To name some, Glycostem could get strong competitors, from Asia or the US for example. At this point, we dont see them yet, but we will have to be aware of that. Also, new technology may someday be developed; a technology that might be cheaper, faster, or just more efficient. This will not happen overnight though, so were not very nervous about that. And finally, we might run out of money. If, for example, investors at a certain point decide to put their money in vaccines instead of cellular therapy, this could immediately affect us. Again, we dont have any signals that this is happening, but its something we will have to be aware of.

In the meantime, Glycostem is working towards the clinical trial initiation and, hopefully, the first real-life proof of a working therapy in the next 24 months or so. Our facilities in Pivot park help us reach those goals. We are part of a tradition and a community that understands what we are doing. Our employees learn from other companies, things come together. Because of our growth plans, we may someday need to move just outside the campus, but for now, this is the perfect place to be. It doesnt prevent Jordansen to look for collaborations elsewhere either: there are strong ties with the Amsterdam UMC, and Glycostem is also part of strong European networks. Teaming up means building your power together.

Troels Jordansen is convinced that every step Glycostem takes is bringing the world closer to the ultimate goal, a cure for cancer. Next milestone: the first results from the patients in the clinical tests that will start later this year. Rest assured that we will all be delighted and relieved the moment we get proof of patients surviving thanks to our therapy.

Glycostem is one of BOMs portfolio companies. This article is part of a series on the Brabant Life Sciences & Health ecosystem. More here.

Also read: A new cancer treatment

Originally posted here:
Mission: a cure to cancer - Innovation Origins

Cartilage Repair/ Cartilage Regeneration Market worth $1,603 million by 2025 – Exclusive Report by MarketsandMarkets – PR Newswire UK

By Gene Therapy Clinics

CHICAGO, Oct. 9, 2020 /PRNewswire/ -- According to the new market research report "Cartilage Repair/ Cartilage Regeneration Market by Treatment modalities (Cell based Type (Chondrocyte Transplantation, Growth Factor), Non-Cell (Tissue Scaffolds)), Application (Hyaline), End User (ASCs, Clinic), Site (Knee) - Global Forecast to 2025", published by MarketsandMarkets, the Cartilage Repair/ Cartilage Regeneration Marketis projected to reach USD 1,603 million by 2025 from USD 787 million in 2020, at a CAGR of 15.3% during the forecast period.

Browse in-depth TOC on "Cartilage Repair/ Cartilage Regeneration Market"

144 Tables 41 Figures 157 Pages

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37493272

The growth of this market is primarily driven by the increasing incidence of osteoarthritis and increasing funding and investments for research in this field.

The cell-based segment accounted for the largest share of the treatment modality segment in the market in 2019.

Based on the treatment modality, the cartilage repair market is segmented into cell-based and non-cell-based approaches. The non-cell-based segment is divided into tissue scaffolds and cell-free composites. In 2019, the cell-based segment accounted for the largest share of the cartilage regeneration market. The large share of this segment can be attributed to technological advancements in stem cell-based therapies for cartilage repair and chondrocyte implantation products

The hospitals segment accounted for the largest share of the end user segment in the cartilage repair market in 2019.

Based on end users, the cartilage regeneration market is segmented into hospitals and ambulatory surgery centers (ASCs) and clinics. The hospitals segment accounted for the largest share of the market in 2019. This can be attributed to the large number of minimally invasive surgeries performed in hospitals and the growing number of hospitals in emerging economies.

Get 10% Customization on this Research Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=37493272

The Asia Pacific region is the fastest growing region of the cartilage repair and regeneration market in 2019.

The Asia Pacific region is estimated to grow at the highest CAGR in the cartilage repair market during the forecast period, this is mainly due to the rising geriatric population and the subsequent increase in the incidence of various disorders and injuries. Recent developments in tissue engineering and stem cell therapy will further fuel market growth.

Prominent players in the cartilage regeneration market are Smith & Nephew plc (UK), DePuy Synthes (US), Zimmer Biomet (US), CONMED Corporation (US), Stryker Corporation (US), and Vericel Corporation (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports:

https://www.marketsandmarkets.com/RequestBundleReport.asp?id=37493272

Browse Related Reports:

Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025

https://www.marketsandmarkets.com/Market-Reports/regenerative-medicine-market-65442579.html

Arthroscopy Instruments Market by Type (Implants, Arthroscope, Visualization System, Surgical Shaver, RF Ablation, Fluid Management), Application (Knee, Hip, Shoulder), End User (Hospitals, Ambulatory Surgery Centers & Clinics) - Global Forecast to 2022

https://www.marketsandmarkets.com/Market-Reports/arthroscopy-instrument-market-238516643.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Aashish Mehra MarketsandMarkets INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cartilage-repair-regeneration-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/cartilage-repair-regeneration.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

Read the original post:
Cartilage Repair/ Cartilage Regeneration Market worth $1,603 million by 2025 - Exclusive Report by MarketsandMarkets - PR Newswire UK

Cryopreservation Equipment Market: Increase in Demand for Regenerative Medicines to Accelerate Market Growth – BioSpace

By Gene Therapy Clinics

Strategic Acquisitions Lead to Innovations in Freezers and Bioproduction of Gene Therapies

Companies in the cryopreservation equipment market are focusing on strategic acquisitions to expand their product portfolio. For instance, BioLife - a manufacturer of cryopreservation freeze media, announced its acquisition of Custom Biogenic Solutions - a producer of cryopreservation equipment for the biotech industry, to expand its portfolio of liquid nitrogen laboratory freezers and other cryogenic equipment.

Strategic acquisitions have led to rise in investments in improving the technology of freezers. As such, freezers segment is expected to account for the highest revenue of the cryopreservation equipment market. The segment is projected to reach a value of ~US$ 3.5 Bn by the end of 2027. Companies are increasing efficacy of cloud-based monitoring systems that help in evaluating biologic sample storage conditions.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=61710

Developments in cryogen techniques have led to innovations in liquid nitrogen laboratory freezers. As such, liquid nitrogen cryogen segment dominates the cryopreservation equipment market and is projected to reach a value of ~US$ 5.1 Bn by 2027. Companies are tapping into opportunities for the development of tools for bioproduction of cell and gene therapies.

Automated Systems in Sample-prep Support Cryo-em Analysis for Protein and Drug Discovery

The cryopreservation equipment market is witnessing innovations in advanced sample preparation systems. For instance, TTP Labtech - a manufacturer of products within sample management, announced the launch of its next-gen automated system for sample-prep. Companies are making efforts to innovate in cryogenic electron microscopy (cryo-EM) in advanced sample preparation systems. As such, sample preparation systems are projected for exponential growth in the cryopreservation equipment market.

Request for Analysis of COVID-19 Impact on Cryopreservation Equipment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=61710

Innovations in sample-prep systems are paving the way for cryo-EM analysis, which is instrumental in protein research and drug discovery. High-quality foil grids in systems for cryo-EM analysis are increasingly replacing manual processes in the healthcare industry. Thus, stakeholders in biotechnology and research laboratories are benefitting from these advanced systems to assess structure of biomolecules and support protein research. Advanced sample-prep systems are pervasively replacing conventional methods of NMR (Nuclear Magnetic Resonance) and X ray crystallography. These systems offer areas for researchers to solve complex protein structures, which was not possible with conventional methods. Improved 3D imaging and high speed blot-free plunging are key attributes that are attracting research companies in the cryopreservation equipment market landscape.

Stem Cell Storage and New Cell Manufacturing Plants Create Income Sources for Companies

Emergence of new cell manufacturing plants is complementing the growth of the cryopreservation equipment market. For instance, Cellex Incorporated - a biotechnology company, announced the launch of its cell manufacturing plant in Cologne, Germany to produce advanced therapy medicinal products for cryopreservation and cell purification, among others.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=61710

Companies in the cryopreservation equipment market are expanding their services in long-term cryo-storage of advanced therapy medicinal products. Thus, manufacturing innovative cell therapy products for cancer is beneficial for creating new income opportunities for manufacturers of cryopreservation equipment. However, growth of the stem cells industry is another driver of the cryopreservation equipment market growth. Growing awareness about stem cell storage at birth is gaining importance in the cryopreservation equipment market landscape.

Cutting-edge Sensor Technology Aids pH and Co2 Measurement in Benchtop Incubators

The cryopreservation equipment market is largely consolidated with three dominant players accounting for a combined share of ~66% of the cryopreservation equipment market. However, difficulty to establish the right culture environment and incubator conditions for laboratories and IVF clinics are some of the challenges faced by emerging players. Hence, manufacturers in the cryopreservation equipment market are increasing production capabilities to develop equipment that provide insights on pH measurement. For instance, Planer a supplier of controlled temperature products, innovated in PetriSenseST, a sensor that provides monitoring of pH and CO2 in benchtop incubators.

Buy Cryopreservation Equipment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=61710&ltype=S

Incubators type segment dominates the cryopreservation equipment market and is projected to reach a value of ~US$ 2.9 Bn by 2027. Hence, equipment companies are increasing technical expertise in sensor technology to support incubator applications in laboratories and IVF clinics. Portability and flexibility of petri dish-sized sensors is gaining application in laboratory equipment. Thus, manufacturers in the cryopreservation equipment market are expected to increase their scope for incremental opportunities by developing advanced sensor equipment to cater to the needs of end users in labs and clinics.

Browse More Trending Reports by Transparency Market Research:

Hemato Oncology Testing Market: https://www.transparencymarketresearch.com/hemato-oncology-testing-market.html

Artificial Muscle Fibers Market: https://www.transparencymarketresearch.com/artificial-muscle-fibers-market.html

Nano Antibodies Market: https://www.transparencymarketresearch.com/nano-antibodies-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/

Link:
Cryopreservation Equipment Market: Increase in Demand for Regenerative Medicines to Accelerate Market Growth - BioSpace

Pediatric Neuroblastoma Treatment Market Share Worldwide Industry Growth, Size, Statistics and Opportunity During 2020 to 2026 – Press Release -…

By Gene Therapy Clinics

This press release was orginally distributed by SBWire

Harrisburg, NC -- (SBWIRE) -- 10/09/2020 -- Global Pediatric Neuroblastoma Treatment Market Size, Status And Forecast 2020-2026

Global Pediatric Neuroblastoma Treatment Market Size research report with COVID-19 impact is considered to be an accurate and deep assessment of the present industrial conditions along with the overall Pediatric Neuroblastoma Treatment market size estimated from 2020 to 2026. The study report also showcases a comprehensive analysis of the leading business programs, Pediatric Neuroblastoma Treatment future market share, and business-oriented planning, etc. The report investigates desirable factors related to the current industrial situations, Pediatric Neuroblastoma Treatment market growth rates, demands, differentiable business-oriented strategies used by the Pediatric Neuroblastoma Treatment market manufacturers/Key players concerning distinct tactics and the futuristic prospects in brief.

Increasing designation of orphan drugs for treating cancers such as neuroblastoma is anticipated to drive the global pediatric neuroblastoma treatment market. For instance, Cellectar Biosciences received orphan drug designation from the U.S. FDA for its CLR 131 Phospholipid Drug Conjugate (PDC) to treat pediatric neuroblastoma patients in early 2018. The drug is currently in Stage 1 of development. The global pediatric neuroblastoma treatment market is anticipate to surge at a staggering CAGR of 9.2% throughout the forecast period (2020-2026).

Inquire here to avail discount on this report:

https://www.marketinsightsreports.com/reports/07102140542/global-pediatric-neuroblastoma-treatment-market-size-status-and-forecast-2020-2026/inquiry?source=Releaswire&Mode=54

The research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Top Companies in the Global Pediatric Neuroblastoma Treatment Market: United Therapeutics,Apeiron Biologics,Pfizer,Bayer,Baxter,Cellectar Biosciences,MacroGenics,... and others.

Pfizer, Inc., another important player in the pediatric neuroblastoma market, is collaborating with BioNTech to co-develop a potential COVID-19 vaccine consisting of mRNA and titled BNT162. Besides this, the company consistently and diligently monitors the supply of its medicines. Owing over 40 owned sites and 200 distributors globally, Pfizer has adequate capacity to distribute its products. So far, the company has not witnessed disruption in its supply chain, with all of their plants in affected areas being operational. The company has increased production, shifted demand to the most critical products, and authorized overtime at many sites to meet patient needs.

Chemotherapy to Register Robust Growth, Immunotherapy Procedures to Follow

The chemotherapy segment is anticipated to bolster prospects for the global pediatric neuroblastoma treatment market. Reduction in cancer growth and bearability of symptoms, and in certain cases, complete eradication of cancers is projected to drive the segment's growth. Additionally, chemotherapy products for neuroblastoma, such as cyclophosphamide, carboplatin and Doxorubicin are found to significantly improve health conditions of children. The chemotherapy segment is poised to expand robustly at a CAGR of 9.2% during the forecast period and shall capture nearly half of the total pediatric neuroblastoma treatment market.

Global Pediatric Neuroblastoma Treatment Market Split by Product Type and Applications:

This report segments the global Pediatric Neuroblastoma Treatment market on the basis of Types are:

Immunotherapy Chemotherapy

On the basis of Application, the Global Pediatric Neuroblastoma Treatment market is segmented into:

Hospitals Clinics Others

Regional Analysis For Pediatric Neuroblastoma Treatment Market:

For comprehensive understanding of market dynamics, the global Pediatric Neuroblastoma Treatment market is analyzed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Order a Copy of This Report at:

https://www.marketinsightsreports.com/report/purchase/07102140542?mode=su?Mode=54

Influence of the Pediatric Neuroblastoma Treatment market report:

-Comprehensive assessment of all opportunities and risk in the Pediatric Neuroblastoma Treatment market.

-Pediatric Neuroblastoma Treatment market recent innovations and major events.

-Detailed study of business strategies for growth of the Pediatric Neuroblastoma Treatment market-leading players.

-Conclusive study about the growth plot of Pediatric Neuroblastoma Treatment market for forthcoming years.

-In-depth understanding of Pediatric Neuroblastoma Treatment market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Pediatric Neuroblastoma Treatment market.

Browse Full Report at:

https://www.marketinsightsreports.com/reports/07102140542/global-pediatric-neuroblastoma-treatment-market-size-status-and-forecast-2020-2026?source=Releaswire&Mode=54

What are the market factors that are explained in the report?

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluates key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

-Analytical Tools: The Global Pediatric Neuroblastoma Treatment Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter's five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Browse Related Reports:

Global Gene Therapy Market Research Report With Opportunities And Strategies To Boost Growth- COVID-19 Impact And Recovery

https://www.marketinsightsreports.com/reports/10082333844/global-gene-therapy-market-research-report-with-opportunities-and-strategies-to-boost-growth-covid-19-impact-and-recovery/inquiry?mode=54

Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Insights And Forecast To 2026

https://www.marketinsightsreports.com/reports/07152146750/global-proliferative-vitreoretinopathy-pvr-therapeutics-market-insights-and-forecast-to-2026/inquiry?mode=54

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

About MarketInsightsReports MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

For more information on this press release visit: http://www.sbwire.com/press-releases/pediatric-neuroblastoma-treatment-market-share-worldwide-industry-growth-size-statistics-and-opportunity-during-2020-to-2026-1308949.htm

Read more from the original source:
Pediatric Neuroblastoma Treatment Market Share Worldwide Industry Growth, Size, Statistics and Opportunity During 2020 to 2026 - Press Release -...

The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% – Yahoo…

By Stell Cell Research

during the forecast period. Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products.

New York, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Regenerative Medicine Market by Product, Application, Geography - Global Forecast to 2025" - https://www.reportlinker.com/p04700208/?utm_source=GNW However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies.The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019.

The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications.In 2019, the oncology segment accounted for the highest growth rate.

This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World.The North America region is projected to grow at the highest CAGR during the forecast period in 2019.

The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

The primary interviews conducted for this report can be categorized as follows: By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35% By Designation: C-level - 30%, D-level - 20%, and Others - 50% By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, and Rest of the World 12%

Lits of companies Profiled in the Report: 3M (US) Allergan plc (Ireland) Amgen, Inc. (US) Aspect Biosystems (Canada) bluebird bio (US) Kite Pharma (US) Integra LifeSciences Holdings Corporation (US) MEDIPOST Co., Ltd. (South Korea) Medtronic plc (Ireland) Anterogen Co., Ltd. (South Korea) MiMedx Group (US) Misonix (US) Novartis AG (Switzerland) Organogenesis Inc. (US) Orthocell Limited (Australia) Corestem, Inc. (South Korea) Spark Therapeutics (US) APAC Biotech (India) Shenzhen Sibiono GeneTech Co., Ltd. (China) Smith & Nephew plc (UK) Stryker Corporation (US) Takeda Pharmaceutical Company Limited (Japan) Tego Science (South Korea) Vericel Corporation (US) Zimmer Biomet (US)

Research Coverage: This report provides a detailed picture of the global regenerative medicine market.It aims at estimating the size and future growth potential of the market across different segments, such as product, application, and region.

The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies.

This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and trends.

Read the full report: https://www.reportlinker.com/p04700208/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

View post:
The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% - Yahoo...

Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat – GlobeNewswire

By Stell Cell Research

October 08, 2020 08:00 ET | Source: Mustang Bio, Inc.

WORCESTER, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that initial Phase 1 data on MB-105, a PSCA-targeted CAR T administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer (mCRPC), will be presented at the virtual 27th Annual Prostate Cancer Foundation Scientific Retreat, which is being held October 20 23, 2020.

Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, We are pleased that City of Hope will be presenting initial data from the Phase 1 trial of MB-105 at the virtual 27th Annual Prostate Cancer Foundation Scientific Retreat. MB-105 is our CAR T cell therapy that is being studied for the potential treatment of prostate cancer. We look forward to continuing to progress this PSCA-targeted CAR T program.

Details of the presentation are as follows:

Title: Clinical Development of PSCA-targeted CAR T cell therapy for mCRPC Session Date and Time:Friday, October 23, 2020, 11:50 a.m. PT Presenter: Tanya Dorff, M.D., Associate Professor, Department of Medical Oncology & Experimental Therapeutics, Head, Genitourinary Cancer Program, City of Hope, Duarte, CA

For more information, please visit the 27th Annual Prostate Cancer Foundation Scientific Retreat website at https://www.pcf.org/scientific-retreat/27th-annual/.

About MB-105 (PSCA CAR T technology) MB-105 was developed in the laboratory of Saul Priceman, Ph.D., assistant professor in City of Hopes Department of Hematology & Hematopoietic Cell Transplantation and a scientist in the T Cell Therapeutics Research Laboratory led by Stephen Forman, M.D., leader of City of Hopes Hematologic Malignancies and Stem Cell Transplantation Institute and the laboratorys director.

The Phase 1 clinical trial of MB-105, one of the first chimeric antigen receptor T cell (CAR T) trials for prostate cancer in the nation, can enroll up to 33 patients. Its primary endpoints are to define the side effects and the best dose of the prostate stem cell antigen (PSCA) CAR T cells in treating patients with PSCA-positive metastatic castration-resistant prostate cancer (mCRPC). Secondary endpoints include assessing the expansion and persistence of PSCA CAR T cells, the clinical response based on Prostate Cancer Working Group 3 (PCWG3) criteria, the survival outcomes and serum cytokine profiles in peripheral blood pre- and post-therapy, as well as describing the PSCA expression level on tumor cells prior to CAR T cell infusion and the relationship it may have with disease response and toxicities. For more information on this Phase 1 trial, please visit http://www.clinicaltrials.gov using identifier NCT03873805.

About Mustang Bio Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (SEC). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit http://www.mustangbio.com.

ForwardLooking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contacts: Jaclyn Jaffe and William Begien Mustang Bio, Inc. (781) 652-4500 ir@mustangbio.com

Investor Relations Contact: Daniel Ferry LifeSci Advisors, LLC (617) 430-7576 daniel@lifesciadvisors.com

Media Relations Contact: Tony Plohoros 6 Degrees (908) 591-2839 tplohoros@6degreespr.com

Read this article:
Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat - GlobeNewswire

Sentien Biotechnologies-Led Team Awarded $2.4M Contract from the US Department of Defense and the Medical Technology Enterprise Consortium – PR Web

By Stell Cell Research

LEXINGTON, Mass. (PRWEB) October 08, 2020

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, has been awarded a $2.4 million contract from the Medical Technology Enterprise Consortium (MTEC). The funds will be used to support the development of a potency assay for mesenchymal stromal cells (MSCs) in regenerative medicine products.

Sentien has partnered with RoosterBio, Inc., a developer of MSCs and bioprocess media, and GenCure, a cell therapy-focused contract development and manufacturing organization (CDMO). Together, this team will develop a potency assay framework using MSCs, spanning large-scale biomanufacturing, in vitro assay development and in vivo biomarker analytics.

The award was granted by the U.S. Army Medical Research & Development Command (USAMRDC) in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (DoD).

The Defense Health Agency has identified a need for quality management in the biomanufacturing of regenerative medicine-based products. For cell therapy products, the potency assay is the most robust quality metric, representing the biological ability of a product to effect a clinical outcome. Developing a potency assay is a complex challenge, requiring significant characterization of process parameters and quality attributes throughout the preclinical and clinical development stages.

This work will take an integrated, cross-functional approach to potency assay development. First, biomanufacturing process parameters and quality attributes will be evaluated during the expansion of MSCs derived from different tissue sources. Second, the resulting cell banks will be analyzed using Sentiens ex-vivo bioreactor platform to assess the immunomodulatory effects of the MSCs and generate putative potency markers. Finally, the putative potency markers will be matched against clinical trial samples from subjects with systemic inflammatory conditions who have been treated with SBI-101, Sentiens lead product.

SBI-101 is a combination biologic product, in which MSCs reside on the exterior of hollow fibers, while blood flows through the interior. The unique design of SBI-101 enables real-time sampling of both MSC-secreted factors (pharmacokinetics) and their effect on patient blood (pharmacodynamics), which will provide particular value for this project. The ultimate goal of the project is to develop a broadly applicable potency assay framework that members of the regenerative medicine community can leverage for their particular biomanufacturing process, product and indication of interest.

Sentien is grateful to MTEC and the DoD for recognizing the potential impact of our proposal and awarding the funds to undertake this work. We have an opportunity to add real value to the regenerative medicine community by developing this potency assay framework which spans R&D, biomanufacturing and clinical translation, said Chris Gemmiti, Senior Vice President of Operations at Sentien. This award demonstrates external recognition of how our proprietary microreactor platform can offer unique insights into MSC biology. This is very timely as the interest in MSCs has been increasingly heightened in the context of COVID-19 trials, said Rita Brcia, Vice President of R&D at Sentien. We are very excited to be partnering with RoosterBio and GenCure on this project, added Sentien CEO, Brian Miller. We believe this team of collaborators, with complementary technologies and skills, will together produce a valuable, widely applicable deliverable.

We are very much looking forward to this collaboration to provide our platform solutions and expertise in MSC manufacturing in support of this project, said RoosterBio CEO, Margot Connor. The development of a MSC potency assay framework is really the cornerstone of a successful regenerative medicine product thus we are grateful for the opportunity to contribute to this team effort.

Becky Cap, Chief Operating Officer for GenCure, a subsidiary of BioBridge Global, commented, GenCure values creative approaches to solving difficult problems, and the Sentien team has developed some highly innovative approaches to treatment with SBI-101. With this project, they are finding ways to leverage that innovation to address more fundamental questions about potency and the impact of tissue source on both potency and therapeutic benefit. We are honored to be part of this project.

About Sentien Biotechnologies

Sentien Biotechnologies, Inc. is a privately-held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentiens lead product, SBI-101, integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, hollow-fiber device. By immobilizing MSCs within a blood-filtration device, SBI-101 enables controlled, dynamic, and sustained delivery of MSC-secreted factors to the patients blood, without the need for direct injection of the MSCs themselves.

SBI-101 has been evaluated in a Phase 1b/2a study in subjects with dialysis-requiring acute kidney injury (AKI-D). An initial readout from the study provides preliminary evidence of anti-inflammatory and wound healing effects consistent with the SBI-101 therapeutic hypothesis. Building on this data, SBI-101 is being investigated in COVID-19 patients suffering from severe systemic inflammation.

Sentiens technology can be applied to additional systemic inflammatory indications in both acute and chronic diseases, focusing on complex conditions where single-factor agents have not been effective. For more information, please visit http://www.sentienbiotech.com.

About RoosterBio, Inc.

RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. http://www.roosterbio.com

About GenCure

GenCure, a subsidiary of San Antonio-based nonprofit BioBridge Global, is focused on enabling the development of cell-based therapies by providing access to source materials, cGMP biomanufacturing experience and clinical research support. Learn more at http://www.gencurebiomanufacturing.org.

About Medical Technology Enterprise Consortium

MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Materiel Command. To find out more about MTEC, visit http://www.mtec-sc.org.

Read more here:
Sentien Biotechnologies-Led Team Awarded $2.4M Contract from the US Department of Defense and the Medical Technology Enterprise Consortium - PR Web

[20202027] Cell Therapy Market Size Expected to Hit $48.11 Billion, At CAGR of 25.6% – GlobeNewswire

By Stell Cell Research

October 08, 2020 09:24 ET | Source: Allied Market Research

Portland, OR, Oct. 08, 2020 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Cell Therapy Market was estimated at $7.75 billion in 2019 and is expected to hit $48.11 billion by 2027, registering a CAGR of 25.6% from 2020 to 2027. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends.

Download Detailed COVID-19 Impact Sample Report at:https://www.alliedmarketresearch.com/request-for-customization/5330?reqfor=covid

High-end technological advancements in the medical field, increase in number of cell therapies in clinical studies, and surge in adoption of regenerative medicines fuel the growth of the market for global cell therapy. On the other hand, high costs of the therapy curtail down the growth to some extent. Nevertheless, high growth potential in emerging markets is expected to pave the way for numerous opportunities for the frontrunners in the industry.

Covid-19 scenario-

The global cell therapy market is analyzed across cell type, therapeutic area, therapy type, end user, and region. Based on cell type, the stem cell segment accounted for nearly three-fifths of the total market share in 2019 and is anticipated to lead the trail by 2027. The same segment would also register the fastest CAGR of 26.1% throughout the forecast period.

Based on therapy type, the allogeneic segment contributed to nearly three-fifths of the total market revenue in 2019 and is expected to rule the roost from 2020 to 2027. The autologous segment, on the other hand, would grow at the fastest CAGR of 26.0% during the study period.

For Purchase Enquiry at:https://www.alliedmarketresearch.com/purchase-enquiry/5330

Based on region, North America held the major share in 2019, generating around half of the global cell therapy market. Simultaneously, Asia-Pacific would portray the fastest CAGR of 31.6% from 2020 to 2027. The other regions covered in the report take in Europe and LAMEA.

The key market players analyzed in the global cell therapy market report include Inc., Osiris Therapeutics, Inc., Medipost Co., Ltd., JCR Pharmaceuticals Co. Ltd., NuVasive, Inc., Stemedica Cell Technologies, Inc., Mesoblast Ltd., Cells for cells, Kolon Tissue Gene, and HolostemTerapieAvanzateS.r.l. These market players have incorporated several strategies including partnership, expansion, collaboration, joint ventures, and others to prove their flair in the industry.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

Top Demanding Reports During COVID-19 Pandemic Period:

Stem Cell Banking Market - Global Opportunity Analysis and Industry Forecast, 20202026

Cell Culture Market - Global Opportunity Analysis and Industry Forecast, 2019-2026

Biosimilars Market - Global Opportunity Analysis and Industry Forecast, 2019-2026

Surgical Power Tools Market - Global Opportunity Analysis and Industry Forecast, 20192026

Consumer Healthcare Market - Global Opportunity Analysis and Industry Forecast, 20192026

Enteric Softgel Capsules Market - Global Opportunity Analysis and Industry Forecast, 20192026

Blood Screening Market - Global Opportunity Analysis and Industry Forecast, 20192026

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Read the rest here:
[20202027] Cell Therapy Market Size Expected to Hit $48.11 Billion, At CAGR of 25.6% - GlobeNewswire

→←